Education
About Us
Working with TipRanks
Follow Us
Cardiol Therapeutics (TSE:CRDL)
TSX:CRDL
CRDL Stock Chart & Stats
C$1.38
-C$0.08(-4.06%)
At close: 4:00 PM EST
C$1.38
-C$0.08(-4.06%)
Day’s Range― - ―
52-Week RangeC$1.09 - C$2.17
Previous CloseN/A
Volume34.34K
Average Volume (3M)136.50K
Market Cap
$138.00M
Enterprise ValueC$116.45M
Total Cash (Recent Filing)$11.62M
Total Debt (Recent Filing)$134.20K
Price to Earnings (P/E)―
Beta2.36
Next Earnings
Apr 01, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding99,997,650
10 Day Avg. Volume86,077
30 Day Avg. Volume136,495
Financial Highlights & Ratios
PEG Ratio-0.23
Price to Book (P/B)5.35
Price to Sales (P/S)0.00
P/FCF Ratio-5.28
Enterprise Value/Market Cap0.84
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.57K
Enterprise Value/Ebitda-3.24
Forecast
1Y Price Target
$11.62Price Target Upside742.34% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical AdvancementsThe results from ARCHER study add clinical evidence to the anti-inflammatory effect of CaridolRx and enhances confidence in the ongoing Phase III MAVERIC study for the drug in recurrent pericarditis.
Efficacy Of CardiolRxThe trial results demonstrated improved multiple cardiac magnetic resonance imaging (CMR) measures of myocardial recovery, heart size, and function following 12 weeks of treatment.
Strategic DevelopmentThe new ARCHER data reinforce the clinical and strategic rationale for advancing CardiolRx across inflammatory cardiac diseases, including myocarditis, cardiomyopathies, and heart failure.
Bears Say
Market PerceptionGiven CRDL’s current ~$98M market capitalization, the market is assigning little to no value to the positive signals seen in ARCHER and missed the fact that the ARCHER trial was an important step to de-risking the potential for CardiolRx in recurrent pericarditis.
Cardiol Therapeutics News
CRDL FAQ
What was Cardiol Therapeutics’s price range in the past 12 months?
Cardiol Therapeutics lowest stock price was C$1.09 and its highest was C$2.17 in the past 12 months.
What is Cardiol Therapeutics’s market cap?
Cardiol Therapeutics’s market cap is $138.00M.
When is Cardiol Therapeutics’s upcoming earnings report date?
Cardiol Therapeutics’s upcoming earnings report date is Apr 01, 2026 which is in 95 days.
How were Cardiol Therapeutics’s earnings last quarter?
Cardiol Therapeutics released its earnings results on Nov 13, 2025. The company reported -C$0.12 earnings per share for the quarter, missing the consensus estimate of -C$0.1 by -C$0.02.
Is Cardiol Therapeutics overvalued?
According to Wall Street analysts Cardiol Therapeutics’s price is currently Undervalued.
Does Cardiol Therapeutics pay dividends?
Cardiol Therapeutics does not currently pay dividends.
What is Cardiol Therapeutics’s EPS estimate?
Cardiol Therapeutics’s EPS estimate is -0.12.
How many shares outstanding does Cardiol Therapeutics have?
Cardiol Therapeutics has 99,997,650 shares outstanding.
What happened to Cardiol Therapeutics’s price movement after its last earnings report?
Cardiol Therapeutics reported an EPS of -C$0.12 in its last earnings report, missing expectations of -C$0.1. Following the earnings report the stock price went down -2.041%.
Which hedge fund is a major shareholder of Cardiol Therapeutics?
Currently, no hedge funds are holding shares in TSE:CRDL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cardiol Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.62 (742.34% Upside)
$11.62 (742.34% Upside)
Insider Transactions
Bought Shares
Worth $150.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 14.8%
Last 30 Days ▼ 14.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.03%
12-Months-Change
Fundamentals
Return on Equity
-341.20%
Trailing 12-Months
Asset Growth
-28.24%
Trailing 12-Months
Company Description
Cardiol Therapeutics
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
CRDL Stock 12 Month Forecast
Average Price Target
C$11.62
▲(742.34% Upside)
Technical Analysis
Theratechnologies
―
Medexus Pharmaceuticals Inc
―
Biosyent
―
HLS Therapeutics Inc
―
BioNxt Solutions
―
Options Prices
Currently, No data available
---